2443487-67-8
2443487-67-8
Chemical Structure
Nivegacetor
Synonym(s): RG6289
- CAS No.: 2443487-67-8
- Formula:C23H25F2N7O2
- Molecular Weight:469.49
InChIKey: YYYGNCPNCFDABE-QWUQOBSTSA-N
SMILES: [H][C@@]1(CC2)CN(C3=CN=NC(OC)=C3)C[C@@]2([H])[C@@H]1NC4=NN(CC[C@H]5OC6=CC(F)=CC(F)=C6)C5=N4
Biological Activity: Nivegacetor (RG6289) a potent and selective γ-secretase modulator. Nivegacetor can reduce the production of Aβ42 can be used for the research of Alzheimer's disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nivegacetor | 99.08% | Nivegacetor (RG6289) a potent and selective γ-secretase modulator. Nivegacetor can reduce the production of Aβ42 can be used for the research of Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tariot P N, et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial[J]. The Lancet Neurology, 2026, 25(2): 147-159. [Content Brief]
- [2]. Mueggler T, et al. Pharmacodynamic effect of a new γ‐secretase modulator, RG6289, on CSF amyloid‐β peptides in a randomized Phase I study[J]. Alzheimer's & Dementia, 2025, 20(Suppl 8): e095213.
